Zonegran (Zonisamide) Patent Expiration, LOE Window & CMS Spending

Zonegran (Zonisamide) by Advanz (Us): Off-Patent Genericized (AB Competition), 7 AB generics, $20.9M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAdvanz (Us)
FDA Application & PathwayN020789 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$20.9M
2024 Medicare Part D Spend$20.9M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 21.4% 2-yr change)